Where Will AbbVie Be in 5 Years?
Most pharmaceutical businesses are slow-moving by nature due to the lengthy amount of time it takes to develop a new medicine ...
AbbVie snaps eight straight sessions of losses
AbbVie (NYSE:ABBV) shares snapped eight consecutive sessions of losses as the stock closed up 0.78% at $166.28. The North ...
FiercePharma1d
With new patient resource to close conversation gaps in rheumatic disease, AbbVie makes 'Rheum for Dialogue'
Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...
BioSpace1d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Buy, Sell, Or Hold AbbVie Stock?
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...
Zacks.com on MSN4d
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
STAT3d
AbbVie’s stumble, Amgen’s tumble, and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Yahoo1d
AbbVie’s Elahere wins European approval for certain ovarian cancers
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...
STAT7d
Despite setback, AbbVie’s big bet on neuroscience has yet to play out
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Pharmabiz11h
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...